drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Adoptive cellular immunotherapy using ex vivo expanded allogeneic gamma-delta (Vγ9Vδ2) T lymphocytes that recognize phosphoantigens via BTN3A1/BTN2A1 and stress ligands via NKG2D to mediate HLA-independent cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Gamma-Delta
drug_category
CULTURED CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Ex vivo expanded allogeneic Vγ9Vδ2 T cells that recognize tumor-associated phosphoantigens via BTN3A1/BTN2A1 and stress-induced ligands via NKG2D, enabling HLA-independent cytotoxicity through perforin/granzyme release and cytokine production.
drug_name
Allogeneic Vγ9Vδ2 T cells
nct_id_drug_ref
NCT05755854